Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Reinstadler, SJ; Kronbichler, A; Reindl, M; Tiller, C; Holzknecht, M; Oberhollenzer, F; Kaser, A; Gauckler, P; Stiermaier, T; Feistritzer, HJ; Mayr, A; Gizewski, ER; Rezar, R; Bugger, H; Eller, K; Eitel, I; Schneider, S; Mayer, G; Thiele, H; Bauer, A; Metzler, B; Lechner, I, , CRP-STEMI, Investigators.
Selective C-reactive protein apheresis in ST-elevation myocardial infarction: Design and rationale of the randomized CRP-STEMI trial.
Am Heart J. 2026; 291:1-9 Doi: 10.1016/j.ahj.2025.07.067
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Bugger Heiko Matthias

Eller Kathrin

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

BACKGROUND: Despite the effectiveness of primary percutaneous coronary intervention (PCI) in treating ST-elevation myocardial infarction (STEMI), myocardial salvage is often incomplete, resulting in large infarct size and an increased risk of heart failure and mortality. Inflammation is involved in this process, with C-reactive protein (CRP) potentially contributing to infarct expansion. Whether selective CRP apheresis in addition to standard care can reduce infarct size in STEMI remains to be determined. TRIAL DESIGN: Selective C-reactive protein apheresis in ST-elevation myocardial infarction (CRP-STEMI) is an investigator-initiated, randomized, open-label (outcome assessor blinded), multicenter trial investigating whether selective CRP apheresis using the PentraSorb-CRP system, in addition to standard care, can reduce infarct size in STEMI patients undergoing PCI within 12 hours of symptom onset. The trial will enroll 202 patients at 5 tertiary care centers in Austria and Germany, randomized 1:1 to either the intervention group (standard care + CRP apheresis) or the control group (standard care). In the intervention group, CRP apheresis will be performed on days 1, 2, and 3 post-PCI. The primary endpoint is infarct size as assessed by late gadolinium enhanced cardiac magnetic resonance at 5 ± 2 days after PCI. OUTLOOK: CRP-STEMI is the first randomized trial to investigate whether selective CRP apheresis, as an adjunct to standard care, can effectively reduce infarct size in acute STEMI patients. TRIAL REGISTRATION: CRP-STEMI, NCT04939805, is registered at https://clinicaltrials.gov/study/NCT04939805.

Find related publications in this database (using NLM MeSH Indexing)

Humans - administration & dosage

ST Elevation Myocardial Infarction - therapy, blood, surgery

C-Reactive Protein - metabolism, isolation & purification

Percutaneous Coronary Intervention - methods

Blood Component Removal - methods

Male - administration & dosage

Randomized Controlled Trials as Topic - administration & dosage

Female - administration & dosage

Middle Aged - administration & dosage

Multicenter Studies as Topic - administration & dosage

© Med Uni Graz • Imprint